Becton Dickinson (BDX) Stock Could Be 15% Undervalued Despite Stent Graft Launch

Becton Dickinson has delivered a 44.4% share price gain over the past year, which puts a spotlight on a basic question for investors who care about valuation. Is the current US$197.88 price tag adequately grounded in the cash flows the business is expected to generate, or has the recent run moved ahead of those fundamentals?

• The 44.4% move over 1 year has materially changed the entry point. Anyone looking at Becton Dickinson today is effectively reassessing what its future cash flows are worth.
• The launch of the Liverty TIPS Stent Graft and the ongoing recalls around BD Phoenix panels both feed into expectations for how reliably the company can turn its medical technology portfolio into long term cash generation, and what kind of investment or quality control spend might sit in front of those inflows.
• If you'd rather focus on earnings, this one's for you. See why Becton Dickinson's 32.7x P/E tells a different valuation story.

The issue now is whether that recent share price performance is consistent with what a Discounted Cash Flow (DCF) view of Becton Dickinson’s cash flows would support.

If you are weighing Becton Dickinson against other opportunities tied to balance sheet strength and fundamentals, it can help to line it up beside companies from our solid balance sheet and fundamentals stocks screener (25 results).

Does Becton Dickinson Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model used here estimates what Becton Dickinson’s potential future cash generation might be worth in today’s dollars. Latest twelve month free cash flow is about $2.55b, and the forecast path assumes those annual cash flows continue to grow over time rather than shrink.

Under those assumptions, the DCF estimate of intrinsic worth is meaningfully above the current US$197.88 share price, which suggests the market is applying a cautious view to those future cash streams. The launch of the Liverty TIPS Stent Graft adds another potential driver for future free cash flow, yet the valuation gap implies investors are still weighing that product expansion against ongoing recall activity and any related quality control spending. Find out what Becton Dickinson could be worth using our Discounted Cash Flow (DCF) estimate.

The Becton Dickinson Narrative: What Would Justify Today's Price?

Narratives on Simply Wall St take Becton Dickinson's valuation puzzle and spell out the specific futures that could justify a higher or lower share price. Each scenario ties its number to a clear view on how growth, margins and risk could evolve, which gives you a reference point to revisit as fresh results, product updates or recall news change the picture over time.

Community views on Becton Dickinson are split between expectations of productivity-driven upside and concern that execution risk already looks priced in.

Bull case: 12% undervalued

"Deployment of next generation pharmacy automation such as the BD Vmax 160 robot and Pyxis Pro systems into health systems creates a platform for software, service and consumables revenue…"

Discover why this Narrative puts Becton Dickinson at 12% undervalued.

Bear case: 20% overvalued

"Even with the BD Excellence operating system currently delivering roughly 8% plant productivity and being extended into commercial and R&D processes, persistent tariff headwinds, regulatory costs and the need to adjust the China cost base may absorb much of these gains…"

Explore why this Narrative puts Becton Dickinson at 20% overvalued.

Before you act on Becton Dickinson's valuation, there is one more angle to check

Becton Dickinson’s numbers tell only part of the story, because independent checks have also picked up potential problem areas that deserve a closer look before you decide what to do next. Take a closer look at 2 warning signs (1 major) before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com